Steroid cell tumors of the ovary are rare, functioning sex cord-stromal ovarian tumors.^[@B1]^ Previously, they were called lipid cell tumors because of their high lipid content.^[@B1],[@B2]^ Two cases demonstrating occurrence of this rare ovarian tumor within the context of von Hippel-Lindau (VHL) disease have been reported.^[@B2],[@B3]^ VHL disease is an autosomal dominant familial inherited syndrome, with varied manifestations depending on the specific mutation. Pancreatic neuroendocrine tumors in association with pheochromocytoma are a classic phenotype of VHL disease,^[@B3]^ but association with steroid tumor of the ovary is a very rare occurrence.

A 17-year-old female with VHL, who had previously undergone adrenal sparing surgeries for bilateral pheochromocytomas, presented to our institution with hirsutism and menstrual irregularity. Serum testosterone was elevated at 269 ng/dL. She received regular screening per VHL alliance guidelines,^[@B2]^ which included imaging of her abdomen, but not the pelvis. MRI showed a hypervascular pancreatic mass with central low signal, corresponding to a calcified pancreatic mass on CT, presumably the neuroendocrine tumor. No virilizing etiology was identified. So, MRI of the pelvis was performed, and this showed an enhancing right adnexal mass not seen separate from the ovary ([Fig. 1](#F1){ref-type="fig"}). It showed drop of signal on pre-contrast T~1~-weighted (T~1~W) opposed phase ([Fig. 2](#F2){ref-type="fig"}) compared to T~1~W in-phase imaging consistent with lipid content within the mass. The mass was later pathologically proven to be steroid cell tumor.

Although germ cell tumors (teratomas) are the most common lipid containing ovarian tumors, they rarely cause virilization. Lipid containing metastasis from clear cell renal cell cancer which can occur with VHL, is a rare possibility. However, these do not cause virilization, and the kidneys were normal in our case. Virilization and menstrual irregularity in our patient raised the suspicion of an androgen-producing ovarian tumor, with the differential diagnosis including Sertoli-Leydig cell tumors, Leydig cell tumors, steroid cell tumors, and less frequently, granulosa-theca tumor.^[@B1]^ Rarely, nonfunctional ovarian tumors like epithelial cystadenomas or cystadenocarcinomas stimulate steroid production in the adjacent normal ovarian stroma and present with hyperandrogenism.^[@B1]^ The combination of lipid content within the ovarian mass (as demonstrated by loss of signal on out-of-phase chemical shift imaging) with virilization pointed to the diagnosis of a steroid cell tumor. There is very little literature on the MRI features of lipid content within such a tumor, which in the setting of virilization and VHL, pointed to the diagnosis in our case. The treatment of choice for symptomatic abdominal tumors in VHL is generally organ sparing resection. Unfortunately, for this young patient with a genetic condition likely predisposing her to such ovarian tumors, she developed a second tumor in her contralateral ovary eventually needing resection of both ovaries.

In conclusion, as most steroid cell ovarian tumors demonstrate high lipid content, exploiting the chemical shift artifact on dual echo gradient-echo (GRE) MRI due to this lipid content may help to clinch the diagnosis in the appropriate clinical context of virilizing features in a case of VHL disease with adnexal mass, as demonstrated in our case.
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![Coronal post-contrast T~1~WI MRI of the pelvis showed an enhancing mass in the right adnexa (arrow), not seen separate from the right ovary. The uterus was normal. T~1~WI, T~1~-weighted image.](mrms-18-251-g1){#F1}

![Axial pre-contrast T~1~WI MRI of the pelvis demonstrating the same mass (arrows) seen on [Fig. 1](#F1){ref-type="fig"}. It showed drop of signal on T~1~W opposed phase (right image) compared to T~1~W in-phase imaging (left image), consistent with lipid content within the mass. T~1~WI, T~1~-weighted image.](mrms-18-251-g2){#F2}
